Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by princeofcuton Jun 17, 2015 12:27pm

173 Views

Post# 23839902

RE:RE:RE:RE:RE:WEBCAST

GV, price action suggests to me (additional to Zenith debacle) that Hepa is pushing for "improvements" that translate into a lower price, as i would've expected the price to vary not much more than +-5%...re. market, PIII is high risk not the entire market and so 18.8M is their target, as best i know FDA and SEC take very dim view of CEO's pumping "off-label" markets...US thing is odd and i suspect no FDA approval yet

Bullboard Posts

HPQ Silicon updates shareholders on Fumed Silica Reactor developments